Inoperative Checkpoint Immunotherapies Rescued Via Companion Targeted Therapies

Ariel Fernandez; L. Ridgway Scott. 28 October, 2018.
Communicated by L. Ridgway Scott.


Immune checkpoint blockers revolutionized cancer therapy. Yet, they met only modest success when treating tumors where regulatory T cells recruited at the tumor periphery overwhelmingly suppress the adaptive immune response. To achieve lasting cure, we propose immuno-tuning combinations with purposely engineered targeted agents that block indirect tumor-induced immunosuppression without adversely impacting the adaptive response.

Original Document

The original document is available in PDF (uploaded 28 October, 2018 by L. Ridgway Scott).